Effects of L-carnitine on serum levels of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide and cardiac function in children with severe hand-foot-mouth disease
PAN Yan-Zhu, SONG Chun-Lan, GUO Yan-Jun, WANG Ling-Ling, CUI Ya-Jie, REN Yi-Fan
Department of Emergency and Critical Medicine, Children's Hospital of Zhengzhou University/Children's Hospital of Henan Province/Zhengzhou Children's Hospital/Zhengzhou Children's Key Laboratory of Critical Care Medicine, Zhengzhou 450003, China
Abstract：Objective To observe the effects of L-carnitine treatment on serum levels of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) and cardiac function in children with heart dysfunction and severe hand-foot-mouth disease (HFMD).Methods A total of 120 children with severe HFMD were enrolled and randomly and equally divided into routine treatment group and L-carnitine treatment group. Thirty healthy children served as the control group. HFMD patients were given anti-fever and antiviral treatment as the basic treatment, while the patients in the L-carnitine treatment group were given L-carnitine as an adjuvant treatment to the basic treatment. Treatment outcomes were observed in the two groups. For all the subjects, serum levels of BNP and NT-proBNP and cardiac function parameters including left ventricular ejection fraction (LVEF), fractional shortening (FS), and cardiac index (CI) were measured at different time points before and after treatment.Results Before treatment, HFMD patients had significantly higher serum levels of BNP and NT-proBNP and heart rate but significantly lower LVEF, FS, and CI compared with the control group (P < 0.05). After treatment, the L-carnitine treatment group had a significantly higher response rate than the routine treatment group (P < 0.05). After 3 days of treatment, the serum levels of BNP and NT-proBNP, LVEF, FS, and CI were significantly reduced in the L-carnitine group (P < 0.05); the L-carnitine group had significantly lower serum levels of BNP and NT-proBNP, LVEF, FS, and CI than the routine treatment group (P < 0.05); there were no significant differences in the serum levels of BNP and NT-proBNP, LVEF, FS, or CI between the L-carnitine treatment and control groups (P > 0.05). After 5 days of treatment, there were no significant differences in the serum levels of BNP and NT-proBNP, LVEF, FS, or CI between the L-carnitine treatment and routine treatment groups (P > 0.05). Heart rate recovery was significantly slower in the routine treatment group than in the L-carnitine treatment group (P < 0.05).Conclusions As an adjuvant therapy for severe HFMD, L-carnitine treatment has satisfactory short-term efficacy in reducing the serum levels of BNP and NT-proBNP and improving cardiac function, thus improving clinical outcomes.
PAN Yan-Zhu,SONG Chun-Lan,GUO Yan-Jun et al. Effects of L-carnitine on serum levels of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide and cardiac function in children with severe hand-foot-mouth disease[J]. CJCP, 2018, 20(8): 635-640.
Bakeet MA, Mohamed MM, Allam AA, et al. Childhood cardiomyopathies:a study in tertiary care hospital in Upper Egypt[J]. Electron Physician, 2016, 8(11):3164-3169.
Chang LY, Hsia SH, Wu CT, et al. Outcome of enterovirus 71 infections with or without stage-based management:1998 to 2002[J]. Pediatr Infect Dis J, 2004, 23(4):327-332.
Fu YC, Chi CS, Jan SL, et al. Pulmonary edema of enterovirus 71 encephalomyelitis is associated with left ventricular failure:implications for treatment[J]. Pediatr Pulmonol, 2003, 35(4):263-268.
Wan SH, McKie PM, Schirger JA, et al. Chronic peptide therapy with B-type natriuretic peptide in patients with pre-clinical diastolic dysfunction (stage B heart failure)[J]. JACC Heart Fail, 2016, 4(7):539-547.
[23]
Ndumele CE, Matsushita K, Sang Y, et al. N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity:the atherosclerosis risk in communities (ARIC) study[J]. Circulation, 2016, 133(7):631-638.
[24]
Vaduganathan M, Claggett B, Packer M, et al. Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure[J]. JACC Heart Fail, 2018, 6(7):564-569.
